Literature DB >> 10852244

GDNF but not BDNF is increased in cerebrospinal fluid in amyotrophic lateral sclerosis.

E Grundström1, D Lindholm, A Johansson, K Blennow, H Askmark.   

Abstract

Cerebrospinal fluid from 15 patients with ALS and 11 controls without neurological disease were analysed for levels of the neurotrophic factors BDNF and GDNF. Analyses were performed using a sensitive sandwich immunoassay (ELISA). There was no significant difference in BDNF levels between the ALS patients and the control subjects studied. Measurable levels of GDNF were found in 12 out of 15 ALS samples. GDNF was not detected in CSF from any of the control subjects. The finding of increased CSF levels of GDNF in ALS compared to controls, together with earlier findings of increased expression of GDNF mRNA in muscle in ALS, indicates that the capacity to synthesize GDNF is enhanced in this disorder.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10852244     DOI: 10.1097/00001756-200006050-00037

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  15 in total

1.  Brain-derived neurotrophic factor is not altered in the serum and cerebrospinal fluid of amyotrophic lateral sclerosis patients.

Authors:  J Iłzecka; Z Stelmasiak
Journal:  Neurol Sci       Date:  2002-03       Impact factor: 3.307

Review 2.  Neuroprotection for amyotrophic lateral sclerosis: role of stem cells, growth factors, and gene therapy.

Authors:  Rachna S Pandya; Lilly L J Mao; Edward W Zhou; Robert Bowser; Zhenglun Zhu; Yongjin Zhu; Xin Wang
Journal:  Cent Nerv Syst Agents Med Chem       Date:  2012-03

Review 3.  The application of biomarkers in clinical trials for motor neuron disease.

Authors:  Jeban Ganesalingam; Robert Bowser
Journal:  Biomark Med       Date:  2010-04       Impact factor: 2.851

Review 4.  The complex molecular biology of amyotrophic lateral sclerosis (ALS).

Authors:  Rachel L Redler; Nikolay V Dokholyan
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

5.  Zirconium oxide ceramic foam: a promising supporting biomaterial for massive production of glial cell line-derived neurotrophic factor.

Authors:  Zhong-wei Liu; Wen-qiang Li; Jun-kui Wang; Xian-cang Ma; Chen Liang; Peng Liu; Zheng Chu; Yong-hui Dang
Journal:  J Zhejiang Univ Sci B       Date:  2014-12       Impact factor: 3.066

6.  Neurotrophic growth factors for the treatment of amyotrophic lateral sclerosis: where do we stand?

Authors:  Alexandre Henriques; Claudia Pitzer; Armin Schneider
Journal:  Front Neurosci       Date:  2010-06-11       Impact factor: 4.677

7.  Preserved expression of fibroblast growth factor (FGF)-2 and FGF receptor 1 in brain and spinal cord of amyotrophic lateral sclerosis patients.

Authors:  Susanne Petri; Klaus Krampfl; Kerstin Kuhlemann; Reinhard Dengler; Claudia Grothe
Journal:  Histochem Cell Biol       Date:  2008-12-19       Impact factor: 4.304

8.  GAS1 is present in the cerebrospinal fluid and is expressed in the choroid plexus of the adult rat.

Authors:  Alberto E Ayala-Sarmiento; Enrique Estudillo; Gilberto Pérez-Sánchez; Arturo Sierra-Sánchez; Lorenza González-Mariscal; Daniel Martínez-Fong; José Segovia
Journal:  Histochem Cell Biol       Date:  2016-05-25       Impact factor: 4.304

9.  Differential expression of c-Ret in motor neurons versus non-neuronal cells is linked to the pathogenesis of ALS.

Authors:  Hoon Ryu; Gye Sun Jeon; Neil R Cashman; Neil W Kowall; Junghee Lee
Journal:  Lab Invest       Date:  2011-01-31       Impact factor: 5.662

10.  Current and emerging treatments for amyotrophic lateral sclerosis.

Authors:  Stefano Zoccolella; Andrea Santamato; Paolo Lamberti
Journal:  Neuropsychiatr Dis Treat       Date:  2009-11-16       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.